{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:18:49Z","timestamp":1781619529069,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017592","name":"Key Science and Technology Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-YBSF-227"],"award-info":[{"award-number":["2023-YBSF-227"]}],"id":[{"id":"10.13039\/501100017592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtct.2024.12.015","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T02:48:13Z","timestamp":1734749293000},"page":"84.e1-84.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Xuezhu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongzhizi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-4204","authenticated-orcid":false,"given":"Fangxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2024.12.015_bib0001","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","article-title":"Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients","volume":"85","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.12.015_bib0002","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2009.75","article-title":"Optimal use of G-CSF administration after hematopoietic SCT","volume":"43","author":"Trivedi","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.015_bib0003","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"1-2","key":"10.1016\/j.jtct.2024.12.015_bib0004","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bbrc.2015.10.116","article-title":"C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling","volume":"468","author":"Sasazawa","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.015_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.12.015_bib0006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-126-9-199705010-00001","article-title":"Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer","volume":"126","author":"Vadhan-Raj","year":"1997","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.015_bib0007","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.12.015_bib0008","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1182\/blood-2023-191091","article-title":"Recombinant human thrombopoietin combined with thrombopoietin receptor agonists can facilitate the recovery of platelet after allogeneic HSCT","volume":"142","author":"Cheng","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.015_bib0009","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.015_bib0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-015-0363-4","article-title":"Eltrombopag: A review of its use in patients with severe aplastic anaemia","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.12.015_bib0011","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1182\/blood-2022-162433","article-title":"Eltrombopag stimulation for neutrophil and platelet recovery following axicabtagene ciloleucel (axi-cel) therapy in lymphoma","volume":"140","author":"Wesson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085197","article-title":"A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy","volume":"13","author":"Peng","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.12.015_bib0013","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jth.15602","article-title":"Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study","volume":"20","author":"Mei","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.015_bib0014","article-title":"Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2024.12.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101948","article-title":"Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation","volume":"81","author":"Wang","year":"2023","journal-title":"Transplant Immunology"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.015_bib0016","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"12","key":"10.1016\/j.jtct.2024.12.015_bib0017","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtct.2024.12.015_bib0018","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed December 30, 2024."},{"issue":"10","key":"10.1016\/j.jtct.2024.12.015_bib0019","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.bbmt.2017.06.010","article-title":"Recombinant human thrombopoietin promotes platelet engraftment and improves prognosis of patients with myelodysplastic syndromes and aplastic anemia after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Wang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jtct.2024.12.015_bib0020","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.12.015_bib0021","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1182\/blood-2022-164490","article-title":"Combination of thrombopoietin receptor agonist and recombinant human thrombopoietin for treating cancer therapy induced thrombopenia","volume":"140","author":"Yan","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.015_bib0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0b013e328356e909","article-title":"Thrombopoietin-receptor agonists","volume":"19","author":"Basciano","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2024.12.015_bib0023","article-title":"Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia","author":"Yang","year":"2024","journal-title":"Pediatr Res"},{"issue":"21","key":"10.1016\/j.jtct.2024.12.015_bib0024","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1002\/cam4.4294","article-title":"Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"10","author":"Gu","year":"2021","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.015_bib0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtct.2024.02.023","article-title":"Recombinant human thrombopoietin promotes platelet engraftment in severe aplastic anemia patients following treatment with haploid hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide","volume":"30","author":"Fu","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.015_bib0026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood.V86.2.703.bloodjournal862703","article-title":"Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin","volume":"86","author":"Matsumura","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2024.12.015_bib0027","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1182\/blood-2005-06-2552","article-title":"Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia","volume":"107","author":"Corazza","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.12.015_bib0028","first-page":"1405","article-title":"Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.015_bib0029","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2009-12-259457","article-title":"Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow","volume":"116","author":"Winter","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jtct.2024.12.015_bib0030","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:03:36Z","timestamp":1769915016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724008340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666636724008340"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}